Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 20/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.52 |
| ▸ | PDE1A | P54750 | 11/20 | 0.52 |
| ▸ | PDE1B | Q01064 | 11/20 | 0.52 |
| ▸ | PDE1C | Q14123 | 11/20 | 0.52 |
| ▸ | PDE5A | O76074 | 4/20 | 0.52 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035765 | 0.92 | PDE7A (0.53) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3020452 | 0.91 | PDE7A (0.55) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3034350 | 0.89 | PDE7A (0.57) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL8117518 | 0.89 | PDE7A (0.59) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL299743 | 0.84 | PDE7A (0.62) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3025967 | 0.83 | PDE7A (0.54) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3029465 | 0.82 | PDE7A (0.53) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3029293 | 0.82 | PDE7A (0.56) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL8117380 | 0.82 | PDE7A (0.47) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL8125589 | 0.78 | PDE7A (0.61) | PDE7APDE4DPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2008142550-A9 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| WO-2008142550-A2 | SPIROCYCLIC DERIVATIVES | PFIZER LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216823-A1 | Spirocyclic Derivatives | PDE7B, PDE6B, PDE7A | PDE7A 3/4885PDE4D 22/4885PDE1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.